What Мифолиан Treats: Main Uses and Benefits

The primary therapeutic utility of Мифолиан (Mifepristone) is used in situations involving certain distressing symptoms and is commonly used to help with symptomatic relief. This medication is used across domains where additional symptomatic support is needed in reproductive health and endocrine management.

Addressing Severe Endocrine and Metabolic Disturbances

This medication is applied across domains where additional symptomatic support is needed for adults dealing with the systemic and metabolic burden associated with Endogenous Cushing's Syndrome. It is a treatment relevant for easing severe manifestations, such as impaired glycemic regulation and the chronic, debilitating functional disturbances arising from prolonged hormone excess. It provides therapeutic support that contributes to easing the overall symptom load.

Non-Surgical Management of Specific Uterine Conditions

In gynecology, Мифолиан is utilized as a non-surgical option that is considered relevant for easing symptoms related to specific uterine conditions. This includes supporting the procedure for early pregnancy termination or the medical management of early pregnancy loss. It is commonly used to help with symptomatic discomfort associated with uterine leiomyomas (fibroids), and may assist in easing symptoms related to blood loss and the associated functional strain. “This approach may assist with maintaining functional stability in patients experiencing heightened uterine symptoms.”

Quick Fact: Relief for Metabolic Symptoms The medication is considered relevant for easing symptoms related to high blood glucose levels in patients with Cushing's Syndrome, which supports general well-being during symptomatic phases.

Мифолиан is generally established for use in adult patients aged 17 years and older. Use is contraindicated and must be avoided by several specific population groups due to risks documented in official labeling. These absolute prohibitions include patients with chronic adrenal failure, those receiving long-term systemic corticosteroid therapy, and individuals with a confirmed or suspected ectopic pregnancy for the termination indication. Use is also strictly contraindicated in patients with hemorrhagic disorders, inherited porphyrias, or a known hypersensitivity to the medicine. An Intrauterine Device (IUD) must be removed prior to use for the termination indication.

Use in other populations is restricted or not established. The medicine is contraindicated during pregnancy for the Cushing’s Syndrome indication, though it is used within gestational limits for the termination indication. Breastfeeding is not recommended during long-term therapy. Safety and efficacy have not been established in pediatric patients or in older adults. Furthermore, a maximum daily dose limit is specified by regulators for adult patients who have renal impairment or mild-to-moderate hepatic impairment (for the Cushing's indication), and use is not recommended in cases of severe hepatic impairment.

Interactions with other medicines and products

Мифолиан (mifepristone) has a significant potential for drug-drug interactions, primarily due to its role as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and its potential to prolong the QTc interval on an electrocardiogram.

Key Interaction Domains

Mechanism/Class	Interaction Consequence	Requirement/Constraint (When Used Long-Term)
Strong CYP3A4 Substrates	Increased plasma concentrations of the substrate drug (e.g., simvastatin, lovastatin, triazolam, midazolam, pimozide, quinidine, sirolimus, tacrolimus, cyclosporine, fentanyl, ergot derivatives).	Contraindicated in long-term use for drugs with a narrow therapeutic index and high first-pass metabolism.
CYP3A4 Inducers	Decreased plasma concentration of Мифолиан.	Use with caution due to potential reduction in effectiveness.
QTc-Prolonging Drugs	Increased risk of QTc prolongation.	Caution and close patient monitoring are advised.

Мифолиан is eliminated slowly from the body, and its inhibitory effect on CYP3A4 may persist for an extended period after the drug has been stopped (up to two to three weeks following chronic administration to steady state). Consequently, this residual interaction potential must be considered when initiating therapy with interacting medicines shortly after discontinuing Мифолиан. Additionally, grapefruit juice is documented to increase Мифолиан's plasma concentrations and should be avoided.

Мифолиан is a synthetic steroid characterized by a dual antagonistic mechanism of action involving two key steroid receptors. The compound acts as a competitive antagonist primarily at the intracellular progesterone receptor (PR) and the glucocorticoid receptor (GR).

At the PR, Мифолиан competes with endogenous progesterone for binding sites. This blockade prevents progesterone from activating the receptor, thereby inhibiting the typical downstream gene expression pathways. This interaction modulates cellular processes in target tissues, including the myometrium and endometrium, increasing myometrial sensitivity to prostaglandin activity and affecting endometrial architecture.

At the GR, Мифолиан competitively binds to the receptor, thereby antagonizing the systemic effects of endogenous cortisol. This interaction blocks cortisol-mediated genomic signaling, resulting in physiological consequences such as the modulation of glucose metabolism at the cellular level.

Мифолиан is administered solely as an oral tablet, but its official usage pattern is strictly structured around two distinct protocols, each governing the dose strength and administration schedule.

Official Usage Protocols

Administration Aspect	Chronic Management (Cushing's Syndrome)	Short-Term Regimen (Reproductive Health)
Dose & Frequency	Starting dose is 300 mg, taken once daily.	A single, once-only dose of 200 mg.
Duration	Intended for long-term, chronic management.	Short-term, single course of treatment.
Specific Condition	Must be taken orally with a meal.	Followed by a second required medication 24 to 48 hours later.

For the chronic management of the endocrine condition, the regimen is designed for long-term use and requires a specialized approach where the dose is gradually increased (titrated) in increments, typically up to a maximum daily dose of 1200 mg. This titration occurs no more frequently than every 2 to 4 weeks. Furthermore, the maximum daily dose is generally limited in patients with mild to moderate hepatic or renal impairment, often not exceeding 600 mg daily.

Conversely, its use for the short-term regimen is a single 200 mg dose that forms the required initial step of a sequential protocol. This 200 mg dose is subject to specific procedural requirements and is dispensed only under a restricted access program. For both protocols, the tablets must be swallowed whole and are not to be split, crushed, or chewed. These structured guidelines define the standardized approach to using the medicine.

Research evidence / Overview of studies for Мифолиан

Evidence for use in Type 2 Diabetes Mellitus

Research has primarily consisted of Randomized Controlled Trials (RCTs). These are studies that monitor measured changes in groups of people receiving Мифолиан compared to groups receiving an inactive substance (placebo) or another agent. Researchers focused on outcomes related to systemic or functional imbalance, such as how measurements of glycated hemoglobin (HbA1c) and fasting plasma glucose evolved during the study period.

In terms of findings, studies report how HbA1c and fasting glucose measurements evolved in the observed populations. Research also described measurements of average body weight during the study period compared to control groups. Findings were observed in some studies to vary; this variability was noted alongside differences in background medications and patient characteristics.

Despite the volume of research, long-term effects are not fully established. Follow-up durations were limited, and information about changes lasting many years is therefore not fully characterized. Existing research provides limited insight into the optimal sequencing or combination with all available concurrent diabetes medications.

---

Evidence for use in Chronic Kidney Disease (CKD)

The agent was evaluated in specific clinical trials designed to focus on populations with Type 2 Diabetes and associated impaired kidney function. Research monitored outcomes related to kidney markers, such as the rate of change in the estimated Glomerular Filtration Rate (eGFR) and albuminuria (protein in the urine).

Findings describe patterns observed in the studies where research described measurements of eGFR that evolved differently over the study period in the observed populations receiving Мифолиан compared to control groups. Studies also described measurements showing shifts in albuminuria levels during the study period. These patterns were observed across various groups of patients with varying degrees of kidney function impairment.

---

Evidence for use in Cardiovascular Risk Reduction

Large-scale, multi-year Cardiovascular Outcome Trials (CVOTs) were conducted specifically to investigate patterns of events in groups observed over time. These trials studies monitored outcomes related to cardiovascular events in the observed populations, such as the first occurrence of Major Adverse Cardiovascular Events (MACE).

The trials data show patterns related to the incidence of MACE events and hospitalization for heart failure (HHF) monitored during the study period in the groups receiving Мифолиан compared to control groups across the long-term follow-up. These patterns were observed in both the population that had established heart disease and the population that had multiple risk factors.

The research provides context but not individual predictions. Although large, results apply only to the populations studied. Limited information for long-term outcomes beyond the set trial period is available, and data for specific groups such as younger adults or those with very few pre-existing cardiovascular risk factors are limited.

Common questions about Мифолиан (FAQ)

---

Q: How quickly does Мифолиан start working after taking it?

The time it takes to see the therapeutic effect can vary based on the condition being treated. For chronic management, the official administration protocol involves gradually increasing the dose over several weeks. Therefore, the full effect may not be noticeable immediately upon starting therapy.

---

Q: After how many days is the effect of Мифолиан noticeable?

Since the dose for chronic management is typically adjusted in increments (titrated) over periods of two to four weeks, a noticeable therapeutic change is expected to be gradual. Effects may take several weeks to fully manifest, as the specific administration schedule involves gradual adjustments over time.

---

Q: How long can the side effects of Мифолиан last?

The duration of side effects is variable. Regulatory information specifically notes that certain effects, such as vaginal bleeding, may last longer than 30 days in some patients. The persistence of any side effect is best addressed by consulting a health professional.

---

Q: Can elderly people take Мифолиан?

Safety and effectiveness have not been formally established in older adults (elderly patients) according to regulatory documents. Guidance on its use in this population is determined by a healthcare professional.

---

Q: How should I store Мифолиан at home?

Official storage instructions state that the tablets must be kept in the original container, which should be tightly closed, at controlled room temperature (between 20 C and 25 C). It is mandatory to store the medicine out of the sight and reach of children and to protect it from light and moisture.

---

Q: Can I split a Мифолиан tablet in half?

No. Official instructions for use explicitly state that the tablets must be swallowed whole and should not be split, crushed, or chewed. This is a mandatory instruction to ensure proper product administration as outlined in the official documentation.

---

Q: With which foods can Мифолиан interact?

Regulatory documents include a specific warning regarding grapefruit juice, which is known to increase the concentration of the medicine in the blood. Regulatory warnings indicate that consumption of grapefruit juice is not recommended while taking this medication.

---

Q: What to do if I miss a dose of Мифолиан?

Official regulatory instructions for chronic use usually outline a specific protocol for managing a missed dose, such as taking it as soon as remembered or skipping it if the next dose is due soon. Patients are typically advised against taking a double dose.

---

Q: What happens if I stop taking Мифолиан suddenly?

Regulatory warnings advise that this medicine should not be stopped suddenly, especially when used for chronic conditions. Stopping abruptly may lead to adverse health effects, and any change in dose must be made gradually under medical supervision.

---

Q: Does Мифолиан affect the ability to drive?

Since common side effects of the medicine include central nervous system effects such as headache and dizziness, caution is advised. Official product information advises caution when driving or operating machinery until the effects of the medicine on the individual are known.

---

Q: Is there an interaction between Мифолиан and contraceptives?

Yes, official regulatory documents warn that this medicine may interfere with the action of hormonal contraceptives. Due to this potential interaction, specific caution and consultation with a healthcare provider are required when these are used together.

---

Q: Is Мифолиан allowed for children, and with what age?

Official prescribing information states that the safety and effectiveness of the medicine have not been established in pediatric patients (children). Use in this age group is typically restricted because safety and effectiveness data are not established.

---

Q: How to take Мифолиан: before or after food?

The administration instructions for chronic management state that the medicine must be taken orally with a meal. This means it should be taken during or shortly after eating, not strictly before or long after a meal.

---

Q: Are the long-term effects of taking Мифолиан known?

Regulatory reviews of the clinical trials note that long-term effects beyond the set trial period are not fully established or characterized. Information about changes lasting many years is limited in the existing research.

---

Q: Do I need to do tests before starting to take Мифолиан?

Yes, regulatory documents indicate that baseline assessments are often necessary. Certain laboratory tests, which may include liver function tests or checks on hormone levels, may be required by a healthcare provider before starting treatment, particularly for long-term use.

---

Q: In what case should the intake of Мифолиан be stopped immediately?

Regulatory warnings state that the medicine may need to be stopped immediately if signs of serious adverse reactions occur. These include symptoms of severe hemorrhage, sepsis, or a severe allergic reaction, all of which require urgent medical attention.

---

Q: Can Мифолиан affect mood?

Yes, regulatory documents list psychiatric disorders among the documented adverse reactions. These can include effects on mood, such as anxiety or depression, and sleep-related disorders.

---

Q: Does Мифолиан help with chronic diseases?

The medicine is specifically indicated for the chronic management of certain endocrine conditions, such as Cushing's Syndrome. It has also been evaluated in clinical trials focusing on chronic conditions like Type 2 Diabetes and Chronic Kidney Disease.

---

Q: Is Мифолиан addictive?

The regulatory information provided by official authorities does not classify the medicine as having a potential for abuse or dependence.

---

Q: Does taking Мифолиан affect weight?

Yes, official regulatory documents list changes in appetite and weight gain among the possible adverse reactions. Any significant or concerning changes in weight should be discussed with a healthcare provider.

How to Store and Dispose of Mifepristone (Мифолиан)

Mifepristone tablets must be stored strictly according to official regulatory specifications to maintain product stability and safety. The required storage temperature is controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with storage not permitted above 30 C. The product must be protected from both light and excess moisture.

Storage and Handling Rules

• Container: Tablets must be kept in the original container and the container must remain tightly closed.
• Prohibitions: The medication must be kept from freezing and should not be stored in environments with excess moisture, such as a bathroom.
• Child Safety: It is a mandatory requirement that Mifepristone be stored out of the sight and reach of children.

Official Disposal Requirements

Unused, expired, or rejected product must be disposed of in accordance with applicable Federal and Local regulations for pharmaceutical waste. Patients should consult their healthcare provider or local waste management office for the official procedure on safely discarding the medicine.